Infliximab biosimilar CT-P13 in Crohn's disease

[1] ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD) [J]. JOURNAL OF CROHNS & COLITIS, 2013, 7 (07) : 586 - 589

[2] European Medicines Agency Committee for Medicinal Products for Human Use, 2013, ASS REP

[3] 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management [J]. JOURNAL OF CROHNS & COLITIS, 2017, 11 (01) : 3 - 25

[4] Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial [J]. LANCET, 2017, 389 (10086) : 2304 - 2316

[5] A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (10) : 1605 - 1612

[6] Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme [J]. JOURNAL OF CROHNS & COLITIS, 2017, 11 (06) : 690 - 696

[7] Biosimilars: the science of extrapolation [J]. BLOOD, 2014, 124 (22) : 3191 - 3196

[8] Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study [J]. LANCET, 2019, 393 (10182) : 1699 - 1707

[9] A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (10) : 1613 - 1620

[10] 2018, LANCET GASTROENTEROL, V3, P404, DOI DOI 10.1016/S2468-1253(18)30082-7

[1] ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD) [J]. JOURNAL OF CROHNS & COLITIS, 2013, 7 (07) : 586 - 589

[2] European Medicines Agency Committee for Medicinal Products for Human Use, 2013, ASS REP

[3] 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management [J]. JOURNAL OF CROHNS & COLITIS, 2017, 11 (01) : 3 - 25

[4] Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial [J]. LANCET, 2017, 389 (10086) : 2304 - 2316

[5] A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (10) : 1605 - 1612

[6] Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme [J]. JOURNAL OF CROHNS & COLITIS, 2017, 11 (06) : 690 - 696

[7] Biosimilars: the science of extrapolation [J]. BLOOD, 2014, 124 (22) : 3191 - 3196

[8] Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study [J]. LANCET, 2019, 393 (10182) : 1699 - 1707

[9] A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (10) : 1613 - 1620

[10] 2018, LANCET GASTROENTEROL, V3, P404, DOI DOI 10.1016/S2468-1253(18)30082-7